On January 9, Stifel increased its price target for Guardant Health, Inc. (NASDAQ:GH) to $120 from $100. The firm maintained a Buy rating. It expects strong volume and average selling price growth in 2026, with publication and reimbursement events that it says will keep investors interested.
Also on January 9, Mizuho raised its price target for Guardant Health to $135 from $120. Mizuho kept an Outperform rating. The firm revised its models for the diagnostics and medical device sectors.
Guardant Health is a precision oncology company. It develops non-invasive liquid biopsy tests for cancer detection, treatment selection, and disease monitoring. Its products include Guardant360 and Guardant Shield. These enable early detection, biomarker profiling, and real-time monitoring to support personalized cancer care.
Guardant Health is placed fifth on a recent list of the Top 10 Oncology Stocks to Buy Now.